NASDAQ:ATHE Alterity Therapeutics Q4 2026 TU Earnings Report $3.78 -0.13 (-3.32%) As of 09/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Alterity Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual Revenue$0.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlterity Therapeutics Announcement DetailsQuarterQ4 2026 TUDate7/30/2026TimeBefore Market OpensConference Call DateWednesday, July 29, 2026Conference Call Time8:00PM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Alterity Therapeutics Earnings HeadlinesAlterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026September 3, 2026 | globenewswire.comAlterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434August 12, 2026 | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth ConferenceAugust 6, 2026 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateJuly 30, 2026 | finanznachrichten.deAlterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateJuly 30, 2026 | globenewswire.comSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) Limited (NASDAQ: ATHE) is an Australia-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on abnormal protein misfolding and aggregation, biological processes associated with disorders such as multiple system atrophy and Parkinson’s disease. The company’s lead drug candidate, ATH-434, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative conditions. Alterity has evaluated ATH-434 in clinical studies involving patients with multiple system atrophy and is also investigating its potential application in Parkinson’s disease and related disorders. Alterity was formerly known as Prana Biotechnology and adopted its current name in 2018. The company conducts its research and development activities in Australia and the United States and is led by Chief Executive Officer David Stamler. Its shares trade on the Nasdaq Capital Market under the symbol ATHE and on the Australian Securities Exchange under the symbol ATH.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
